INSTITUTION'S PROFILE
Gilead Sciences, Foster City, CA, USA.
Publications (6)
Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
Journal: The lancet. HIV
Publication date: 2018
Journal: The lancet. HIV
Publication Year: 2018
Fee for home delivery and monitoring of antiretroviral therapy for HIV infection compared with standard clinic-based services in South Africa: a randomised controlled trial.
Journal: The lancet. HIV
Publication date: 2022
Journal: The lancet. HIV
Publication Year: 2022
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.
Journal: Lancet (London, England)
Publication date: 2021
Journal: Lancet (London, England)
Publication Year: 2021
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial.
Journal: The lancet. HIV
Publication date: 2023
Journal: The lancet. HIV
Publication Year: 2023
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
Journal: Lancet (London, England)
Publication date: 2022
Journal: Lancet (London, England)
Publication Year: 2022
Efficiency of 6-month PrEP dispensing with HIV self-testing in Kenya: an open-label, randomised, non-inferiority, implementation trial.
Journal: The lancet. HIV
Publication date: 2022
Journal: The lancet. HIV
Publication Year: 2022